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transduced. Ten years after the last cell infusion, real-time PCR
analysis for the presence of vector sequences in these patients
revealed that ∼18% of peripheral blood mononuclear cells (PBMCs)
from patient 1 carried the vector, whereas <0.1% of LASN-marked
PBMCs were detectable in the second patient. Although no serious
adverse events have been observed in either patient, the recent events
of insertional oncogenesis in X-linked severe combined
immunodeficiency patients treated with retroviral-mediated gene
transfer prompted us to study the integration sites in lymphocytes
from our patients with the aim of mapping the regions involved by
the retroviral integration events, determining their localization with
respect to known genes, and assessing whether recurrent patterns
could be identified. Genomic DNA was prepared from stored
PBMCs samples dating 1991, 1992, 1995, and 1996 and from 9
lymphocytic single cell clones established in 1998. Using the “inverse
PCR” technique (Nolta et al. PNAS 1996; 93: 2414) we isolated
∼105 integration sites from bulk PBMC samples and ∼20 integration
sites from single cell clones. To date, 34 of these sequences have
subjected to detailed analysis. We used MegaBLAST (http://
www.ncbi.nlm.nih.gov/blast/megablast.html) to compare the
sequences to the Nov 2002 (build 31) assembly of the human genome
and identified eleven sequences that mapped to a unique position in
the human genome. The positions of 15,000 known genes have been
determined by aligning mRNA Reference Sequences to the human
genome (genome.ucsc.edu). We determined whether any of the eleven
integration sites occurred within 10 kb of one of these known genes.
We found one sequence within an intron of the androgen induced
protein (AIG-1) gene, one sequence within an intron of the ubiquitin-
conjugating enzyme E2L 3 (UBE2L3) gene, and one sequence 9 kb
upstream of interleukin 1 receptor antagonist (IL1RN) gene. The
remaining sequences mapped >10 kb from known genes or did not
return significant similarities. Overall, our results indicate that this
technique can be used to map retroviral integration sites both from
bulk PBMC populations as well as single cell clones. In addition,
this preliminary analysis would suggest that the integration events
of the LASN vector largely did not occur within the coding regions
of genes. Finally, one integration site isolated from the 1996 bulk
PBMC sample was recovered also from two of the single cell clones
generated 2 years later, thus demonstrating that this approach can
be applied to tracking and longevity studies.
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Due to a heightened awareness of the potential for adverse events
during human gene therapy trials, it is important to even more
carefully document the safety of the vectors and to examine the
potential for insertional mutagenesis from integrating vectors, using
long-term in vivo systems combined with molecular analyses. We
describe a system to assess the potential for generation of replication–
competent retrovirus (RCR) and insertional mutagenesis in vivo, in
immune deficient mice, followed by PCR and inverse PCR to examine
integration sites. Human hematopoietic stem cells and human
mesenchymal stem cells carrying two different Moloney-based
vectors were co-transplanted together into immune deficient mice
that are unable to reject cells that become transformed. The
sensitivity of the system was initially verified using N2, a vector
with known potential to generate recombinants (Donahue et al.,
1992). The N2 vector does not have the safety modifications now
implemented in the LN-based vectors and packaging systems
currently used in clinical trials (Lynch and Miller, 1991). Murine
lymph node tumors arose in eleven of the twelve mice that received
the N2-transduced human cells by IV transplantation. The neo gene
was transferred to murine cells, as well as being present in human
cells in each mouse, and caused a significant lymphoproliferation in
the murine pre-T cells. It took five months for the leukemia to arise
in those mice, and then they became extremely sick rapidly, with
five of the twelve mice moribund at the same timepoint, and the
others moribund within a one month period. Next, a total of 481
mice were monitored for adverse events from safety-modified vectors
for 7-18 months post-transplantation. Mice that displayed any
sign of ill health were killed, autopsied, and subjected to a full range
of biosafety studies. No evidence of insertional mutagenesis causing
human leukemia or solid tumors in any mouse was detected. No
RCR were detected from the safety-modified retroviral vectors in
117 serum samples analyzed by vector rescue assay. In addition, 61
mice transplanted with human progenitors that had been transduced
with HIV-1–based lentiviral vectors, and followed for 2-6 months,
were assessed using similar techniques. No adverse events were
caused by the vectors and no mouse tested had HIV p24 protein in
their serum. The current studies provide a sensitive in vivo system
to assess potential risk from replication competent vectors and
from insertional mutagenesis when retroviral or lentiviral vectors
are considered as candidates for human gene therapy.
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A principal concern regarding the safety of HIV1 based lentiviral
vectors is replication competent lentivirus (RCL). We have developed
two PCR assays for detecting RCL. The first assay detects
recombination between the transfer vector and the packaging
construct (psi-gag) and for a positive control we utilized pHIV-
GFP which contains the intact psi-gag sequence. Analysis of PCR
products by probing with a radiolabeled oligo revealed the sensitivity
of detection of psi-gag to be ~ 10-100 copies of HIV-GFP in a
background of 0.1μg of uninfected DNA (three independent
experiments). The second assay we developed uses real time PCR
to analyze vesicular stomatitis virus glycoprotein (VSVG) envelope
DNA and has a detection limit of ~5-50 VSVG sequences in a
background of 0.1μg of uninfected DNA. In an attempt to further
increase the sensitivity of our detection assays, we sought to first
amplify RCL on a permissive cell line – a step which will be dependent
on the infectability of the cell line and the rate of RCL production.
To address infectivity, we utilized a variety of cell lines (C8166,
Sup-T1, CEM-SS, H9, 293 and HeLa-T4) to titer a stock VSVG
pseudotyped lentiviral vector, RRL-CMV-GFP. Of the six cell lines
tested, highest titer was obtained in the C8166 and 293 cell lines
(2.9 x 106 TU/ml, and 1.3 x 106 TU/ml respectively). We next
evaluated the ability of two cell lines (C8166, HeLa-T4) to amplify
an attenuated HIV1 virus, R7-GFP. p24 was measured every two
days for a week and a ~100 fold increase was observed by day six
(300pg/ml) for C8166 where as HeLa-T4 had a minimal increase.
After selecting C8166 as the amplification cell line, we compared
the sensitivity of PCR and p24 ELISA. C8166 cells were infected
with R7-GFP at tenfold dilutions (between 10-4 to 10-7) and each
culture was analyzed by psi-gag PCR and P24 ELISA after two
weeks. At the 10-4 dilution, 6/6 replicates were positive by PCR and
ELISA, while 3/6 and 1/6 replicates were positive at the 10-5 dilution
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for psi-gag and p24 respectively. In subsequent experiments, C8166
and 293 cells were transduced with vectors and screened for RCL
weekly for 3 weeks. Psi-gag recombinants were routinely detected
in cells transduced with the 4-plasmid based RRL-CMV-GFP vectors
(4/4) but only occasionally in safety modified vectors that lack
homology between transfer and packaging plasmid (Genetix, Inc).
p24 levels above baseline were also observed (3/6), especially when
testing concentrated vector. VSV-G sequences were not routinely
detected. Cells exposed to media collected after 3 weeks of
amplification had no evidence of psi-gag, VSVG or p24 antigen
transfer, indicating that the signal detected in the amplification cells
did not represent a true RCL. In conclusion, we have developed a
sensitive method for RCL detection and demonstrate transfer of
packaging sequence to transduced cells. To date, RCL has not been
detected.
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The development of a safe lentiviral packaging system able to
generate high titer virus free of contaminating RCL is essential for
future gene therapy trials. One of the most critical safety measures
for the prevention of RCL and pre-RCL contamination is the splitting
of GAGPOL. We and others (Wu et al., EMBO, 1997) have reported
split packaging systems in which the GAGPOL is dissociated onto
two separate plasmids.  One plasmid encodes the GAG polyprotein
and PR. This plasmid expresses a POL-less GAG protein, which
localizes to the budding virions through myristilation of its N-terminal
amino acid.  The second plasmid expresses a VPR-RT-IN fusion
protein, which is tethered to the budding virions through the
interaction of VPR with P6.  However, viral titers obtained by the
split GAGPOL system were 10 fold lower than packaging systems
in which the GAGPOL was not split. We hypothesized that the
decrease in viral titers might be caused by suboptimal polyprotein
processing by PR, possibly due to steric hindrance of PR by GAG
upon separation from RT-IN. To investigate this possibility, we
generated S35 labeled recombinant lentivirus using split and non-
split packaging systems and analyzed their protein composition. In
contrast to virus generated with the non-split packaging system,
virus generated with the split packaging system showed high levels
of unprocessed RT-IN polyprotein strongly suggestive of suboptimal
protease activity.  To determine whether PR activity, and therefore
viral titers, could be rescued, we further split GAG-PR onto two
separate plasmids.  One plasmid encodes the GAG polyprotein in
which the frameshift for POL and the 207bp overlap with PR has
been eliminated.  The second plasmid expresses a VPR-PR fusion
protein, which like the VPR-RT-IN fusion protein, is tethered to
the budding virions through the interaction of VPR with P6.  Analysis
of S35 labeled viral particles showed more efficient processing of
GAG and VPR-RT-IN when PR is supplied in trans as VPR-PR
fusion protein.  Importantly, titer analysis of the various packaging
systems showed that supersplitting PR away from GAG greatly
increased viral titers to levels 3 fold lower than those obtained with
the non-split packaging systems.  Next, to increase safety and
determine whether viral titers could be rescued further, a 400bp
fragment was deleted from the U3 region of the right LTR, and the
U5 region was completely removed and replaced by an strong polyA/
termination signal.  These modifications resulted in a further 2 fold
increase in viral titers. To demonstrate the efficacy of our “supersplit”
packaging system with the SIN β 87-globin lentiviral vector, human
cord blood cells were transduced, and then transplanted into NOD/
SCID mice.  At 24 weeks post transplantation globin was quantified
by HPLC.  The total hβ-globin expression was comprised of 57%
hβ 87-globin.  Here we demonstrate that the use of safety
modifications such as the supersplit packaging system combined
with a SIN vector can greatly increase safety of lentiviral vector
systems without a loss in viral titers or efficacy.
7. When a Self Inactivating (SIN) Vector  Is
Not a SIN: Characterization of Episomal HIV-1
Vector Forms
Hong Ma,1 Tal Kafri.1
1Gene Therapy Center, University of North Carolina at Chapel
Hill, Chapel Hill, NC, United States.
The fact that relatively large quantities of episomal vector forms
are generated during retroviral vector transduction prompted us to
investigate the mechanism by which non-integrating HIV-1 vector
structures are formed, and to identify potential biosafety risks which
may be posed by these episomal vector DNA structures, shortly
after transduction. As a first step in this study, we have developed
a shuttle HIV-1 vector which allows clonal isolation of circular
HIV-1 DNA forms in bacteria. Using the shuttle HIV-1 vector, we
were able to characterize the effect of HIV-1 integrase on the
formation of circular vector DNA structures. Isolated circular vector
forms were then used to develop a novel single LTR HIV-1 vector,
which reduces the likelihood of recombination and rearrangements
between the vectors’ LTRs. We developed a variety of single-LTR
HIV-1 vector constructs, which allowed production of high titer
vector particles through transient three-plasmid transfection.
Following integration, these vectors containing either a CMV or a
tetracycline inducible promoter allowed high levels of constitutive
or regulated transgene expression, respectively. More importantly,
using integrase-mutant containing vector particles, we could show
that episomal vector forms generated during transduction of
packaging cells served as efficient templates for vector particle
production. To our surprise, deletion of the U3 region from a single
LTR vector construct did not reduce vector titers following three-
plasmid transfection, thus indicating that single-LTR vector structures
generated during transduction with traditional self-inactivating
vectors, can serve as templates for vector production. To test this
hypothesis, a SIN lentiviral vector was used to transduce HIV-1
packaging cells. Two days post-transduction, vector particles
collected from conditioned media showed a titer of up to 105 IU/ml.
Interestingly, dilution of the non-integrated vector forms during four
weeks of culture resulted in a reduction of vector titers to less than
102 IU/ml.  This observation indicated that the ability of SIN vectors
to serve as efficient templates for vector production is restricted to
their episomal forms, rather than their integrated genomes, which
are not lost during cell division. To better characterize the mechanism
by which full-length vector RNA is transcribed from episomal SIN
vectors, 5’ RACE analysis was carried on RNA extracted from SIN
and Non-SIN vector-particles. The result of this analysis revealed
that the 5’ end of RNA molecules transcribed from a circular single-
LTR SIN construct started 70-75n upstream of the beginning of the
R region.
In conclusion:
A) Single-LTR HIV-1 vector constructs allow efficient production
of high titer vector particles.
B) This study opens new avenues in retroviral vector design,
which improve vector biosafety and broaden the spectrum of HIV-
1 vector applications.
C) More importantly this study demonstrated that circular U3
deleted vectors, which are formed during transduction should not be
regarded as self-inactivating.
